Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2016 - 2025)

Lineage Cell Therapeutics' Current Deferred Revenue history spans 16 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 54.89% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, down 54.89%, while the annual FY2025 figure was $3.3 million, 54.89% down from the prior year.
  • Current Deferred Revenue reached $3.3 million in Q4 2025 per LCTX's latest filing, down from $3.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $38.9 million in Q3 2022 to a low of $101000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $11.9 million, with a median of $9.3 million recorded in 2022.
  • The largest YoY upside for Current Deferred Revenue was 18019.0% in 2021 against a maximum downside of 97.88% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $18.1 million in 2021, then tumbled by 48.0% to $9.4 million in 2022, then grew by 14.72% to $10.8 million in 2023, then crashed by 31.64% to $7.4 million in 2024, then tumbled by 54.89% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Current Deferred Revenue are $3.3 million (Q4 2025), $3.8 million (Q3 2025), and $5.3 million (Q2 2025).